2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      NQO1 regulates pharmaco-behavioral effects of d-amphetamine in striatal dopaminergic system in mice

      , , , , , , ,
      Neuropharmacology
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: not found
          • Article: not found

          Dopamine, learning and motivation.

          Roy Wise (2004)
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The neural basis of drug craving: An incentive-sensitization theory of addiction

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The nature of dopamine dysfunction in schizophrenia and what this means for treatment.

              Current drug treatments for schizophrenia are inadequate for many patients, and despite 5 decades of drug discovery, all of the treatments rely on the same mechanism: dopamine D(2) receptor blockade. Understanding the pathophysiology of the disorder is thus likely to be critical to the rational development of new treatments for schizophrenia. To investigate the nature of the dopaminergic dysfunction in schizophrenia using meta-analysis of in vivo studies. The MEDLINE, EMBASE, and PsycINFO databases were searched for studies from January 1, 1960, to July 1, 2011. A total of 44 studies were identified that compared 618 patients with schizophrenia with 606 controls, using positron emission tomography or single-photon emission computed tomography to measure in vivo striatal dopaminergic function. Demographic, clinical, and imaging variables were extracted from each study, and effect sizes were determined for the measures of dopaminergic function. Studies were grouped into those of presynaptic function and those of dopamine transporter and receptor availability. Sensitivity analyses were conducted to explore the consistency of effects and the effect of clinical and imaging variables. There was a highly significant elevation (P.<001) in presynaptic dopaminergic function in schizophrenia with a large effect size (Cohen d=0.79). There was no evidence of alterations in dopamine transporter availability. There was a small elevation in D(2/3) receptor availability (Cohen d=0.26), but this was not evident in drug-naive patients and was influenced by the imaging approach used. The locus of the largest dopaminergic abnormality in schizophrenia is presynaptic, which affects dopamine synthesis capacity, baseline synaptic dopamine levels, and dopamine release. Current drug treatments, which primarily act at D(2/3) receptors, fail to target these abnormalities. Future drug development should focus on the control of presynaptic dopamine synthesis and release capacity.
                Bookmark

                Author and article information

                Journal
                Neuropharmacology
                Neuropharmacology
                Elsevier BV
                00283908
                June 2020
                June 2020
                : 170
                : 108039
                Article
                10.1016/j.neuropharm.2020.108039
                32165217
                5e9ad160-20f2-431c-b901-673e3ec4b87e
                © 2020

                https://www.elsevier.com/tdm/userlicense/1.0/

                History

                Comments

                Comment on this article